Vamil Divan is ranked #704 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Vamil Divan (Guggenheim) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Vamil Divan's stock ratings?

About 53% of Vamil's ratings were profitable over a one-year hold, with an average return of +22.1% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Vamil Divan

GUGG

Vamil Divan

Guggenheim

Wall Street Analyst

★★★★☆

#704

on 13Foresight · ranked by our own returns

55%

Success Rate

+22.2%

Average Return

30 of 55 calls profitable · -12.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 55% of Vamil Divan's ratings turned a profit when each position was held for 1 year — averaging +22.2% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

113 Buy 9 Hold 0 Sell

Vamil's Stock Coverage 56 ratings · 2026-06-24

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ABSI AbSci	Jun 14, 2026	BUY	Strong Buy +32.2% avg upside 18 analysts	$15.00 90.28% Upside	+1.9%
VERA Vera Therapeutics	Jun 05, 2026	BUY	Strong Buy +75.4% avg upside 19 analysts	$56.00 47.82% Upside	+8.7%
TVTX Travere Therapeutics	Jun 05, 2026	BUY	Strong Buy -16.2% avg upside 22 analysts	$56.00 0.66% Upside	+22.1%
JNJ Johnson & Johnson	Jun 05, 2026	BUY	Strong Buy -6.2% avg upside 36 analysts	$266.00 12.90% Upside	+2.6%
MRK Merck & Company	Jun 02, 2026	BUY	Strong Buy +7.4% avg upside 43 analysts	$140.00 18.72% Upside	-1.5%
PFE Pfizer	Jun 01, 2026	BUY	Buy +35.8% avg upside 45 analysts	$36.00 44.89% Upside	-2.1%
JBIO Jade Biosciences	Jun 01, 2026	BUY	Strong Buy +173.1% avg upside 16 analysts	$47.00 128.73% Upside	-9.5%
ASMB Assembly Biosciences	May 28, 2026	BUY	Strong Buy +29.8% avg upside 10 analysts	$43.00 60.87% Upside	·
UNCY Unicycive Therapeutics	May 12, 2026	BUY	Strong Buy +578.8% avg upside 10 analysts	$37.00 346.86% Upside	-1.1%
SVRA Savara	May 12, 2026	BUY	Strong Buy +50.8% avg upside 17 analysts	$11.00 90.04% Upside	-1.0%
ANIP ANI Pharmaceuticals	May 10, 2026	BUY	Strong Buy +24.2% avg upside 11 analysts	$124.00 50.02% Upside	·
INSM Insmed	May 07, 2026	BUY	Strong Buy +74.3% avg upside 36 analysts	$226.00 119.41% Upside	+0.0%
SE:VICO Vicore Pharma Holding AB	May 06, 2026	BUY	Strong Buy +196.7% avg upside 2 analysts	$38.00 216.10% Upside	·
AMGN Amgen	May 03, 2026	HOLD	Buy -13.8% avg upside 57 analysts	$340.00 2.17% Downside	+8.0%
ABBV AbbVie	Apr 30, 2026	BUY	Buy -4.2% avg upside 43 analysts	$249.00 6.40% Upside	+7.2%
VALN Valneva	Apr 16, 2026	BUY	Buy +107.1% avg upside 5 analysts	$11.00 103.05% Upside	-4.9%
ELDN Eledon Pharmaceuticals	Mar 20, 2026	BUY	Strong Buy +308.1% avg upside 10 analysts	$8.00 106.20% Upside	+31.9%
PROK ProKidney	Jul 13, 2025	BUY	Buy +265.9% avg upside 12 analysts	$7.00 279.42% Upside	-50.7%
KROS Keros Therapeutics	May 29, 2025	HOLD	Buy +131.4% avg upside 21 analysts	—	-25.1%
FR:GNFT Genfit	Mar 31, 2025	BUY	Strong Buy +172.3% avg upside 5 analysts	$9.00 18.33% Downside	·
SCYX SCYNEXIS	Mar 19, 2025	BUY	Strong Buy +248.1% avg upside 10 analysts	$5.00 26.93% Upside	-16.8%
GOSS Gossamer Bio	May 06, 2024	HOLD	Buy +4317.3% avg upside 17 analysts	—	+39.7%
RLMD Relmada Therapeutics	Jun 15, 2023	BUY	Buy +102.0% avg upside 15 analysts	$26.00 279.07% Upside	+18.0%
XERS Xeris Pharmaceuticals	Jul 22, 2022	HOLD	Strong Buy +29.8% avg upside 10 analysts	—	+68.9%
DNTH Dianthus Therapeutics	Jul 22, 2022	HOLD	Strong Buy +2.7% avg upside 29 analysts	—	-57.0%
CFRXQ ContraFect	Jul 22, 2022	HOLD	Buy +10969999900.0% avg upside 10 analysts	—	·
LLY Eli Lilly & Co	Jul 22, 2022	HOLD	Buy -10.7% avg upside 47 analysts	—	+42.2%
AXSM Axsome Therapeutics	Jun 27, 2022	BUY	Strong Buy -8.2% avg upside 28 analysts	$49.00 80.32% Downside	+125.1%
EOLS Evolus	Jun 21, 2022	BUY	Strong Buy +114.7% avg upside 9 analysts	$15.00 124.48% Upside	-28.8%
ACAD ACADIA Pharmaceuticals	Jun 17, 2022	HOLD	Strong Buy +59.9% avg upside 42 analysts	$27.00 19.97% Upside	+23.4%
CABA Cabaletta Bio	May 24, 2022	BUY	Strong Buy +362.4% avg upside 16 analysts	$10.00 232.17% Upside	+702.3%
ALKS Alkermes	May 24, 2022	BUY	Strong Buy -21.0% avg upside 34 analysts	$36.00 24.25% Downside	+3.5%
ROIV Roivant Sciences	May 22, 2022	BUY	Strong Buy +1.1% avg upside 17 analysts	$6.00 80.92% Downside	+164.7%
TBPH Theravance Biopharma	May 22, 2022	BUY	Buy +10.7% avg upside 18 analysts	$12.00 28.73% Downside	+16.7%
VRTX Vertex Pharmaceuticals	May 22, 2022	HOLD	Strong Buy -5.9% avg upside 61 analysts	$265.00 43.53% Downside	+26.7%
SNY Sanofi	May 22, 2022	BUY	Strong Buy +76.5% avg upside 20 analysts	$138.27 231.65% Upside	-2.1%
REGN Regeneron	May 22, 2022	BUY	Strong Buy +25.6% avg upside 57 analysts	$738.00 19.53% Upside	+10.2%
HALO Halozyme	May 22, 2022	BUY	Buy -15.0% avg upside 20 analysts	$52.00 25.71% Downside	-21.1%
NBIX Neurocrine	May 04, 2022	HOLD	Strong Buy +5.7% avg upside 37 analysts	$95.00 41.51% Downside	+8.4%
ARQT Arcutis Biotherapeutics	Sep 21, 2021	BUY	Strong Buy +48.0% avg upside 14 analysts	$58.00 117.45% Upside	-17.1%
DCF BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc.	Aug 12, 2021	BUY	Hold +36730.1% avg upside 2 analysts	—	·
ACGP Associated Capital Group	May 07, 2021	BUY	Strong Buy +41.0% avg upside 9 analysts	$37.00 8.66% Upside	·
TEVA Teva Pharmaceutical	Jul 10, 2019	HOLD	Buy -10.4% avg upside 39 analysts	—	+28.1%
IRWD Ironwood Pharma	Jul 10, 2019	HOLD	Buy +209.6% avg upside 23 analysts	—	-6.7%
TLPH Talphera	Jul 10, 2019	BUY	Buy +357.3% avg upside 15 analysts	—	-63.1%
BMY Bristol-Myers Squibb	May 29, 2019	HOLD	Buy +6.8% avg upside 42 analysts	$55.00 0.67% Downside	+35.9%
LKFT Lakefront Biotherapeutics	Dec 13, 2018	BUY	Buy +264.3% avg upside 24 analysts	—	·
IRMD Iradimed	Nov 27, 2017	BUY	Strong Buy -9.2% avg upside 6 analysts	$19.00 79.48% Downside	+112.8%
CRVS Corvus Pharmaceuticals	Aug 23, 2017	HOLD	Strong Buy +104.4% avg upside 14 analysts	—	-24.8%
ESPR Esperion	Mar 20, 2017	HOLD	Buy +699.5% avg upside 22 analysts	$29.00 817.79% Upside	+79.5%
BIIB Biogen	Aug 02, 2016	HOLD	Buy +23.9% avg upside 51 analysts	$322.00 60.86% Upside	-12.8%
PDSB PDS Biotechnology	Oct 26, 2015	BUY	Strong Buy +1530.6% avg upside 11 analysts	$29.00 2946.85% Upside	-50.6%
MYGN Myriad Genetics	Feb 04, 2015	SELL	Hold +310.8% avg upside 24 analysts	$30.00 562.95% Upside	-4.2%
ILMN Illumina	Jan 28, 2015	BUY	Buy -11.2% avg upside 30 analysts	$230.00 40.47% Upside	-22.0%
GILD Gilead Sciences	Apr 14, 2014	BUY	Strong Buy -5.8% avg upside 66 analysts	—	+53.0%
A Agilent	Mar 05, 2013	BUY	Strong Buy +3.9% avg upside 32 analysts	$48.00 62.18% Downside	+36.9%

🔒 51 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Vamil Divan — Frequently Asked Questions

How accurate are Vamil Divan's stock ratings?

Based on the calls 13Foresight could measure, about 53% of Vamil's ratings were profitable over a one-year hold, with an average return of +22.1% per rating, or -13.0% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Vamil ranked on 13Foresight?

Vamil Divan is currently ranked #704 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Vamil cover?

Vamil most recently has ratings on ABSI, VERA, TVTX, JNJ, MRK, PFE, JBIO, ASMB, UNCY, SVRA, ANIP, INSM and 44 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!